NEW YORK, NY / September 28, 2022 / CLS Therapeutics, an oncology-focused gene therapy company that utilizes Extracellular DNA and NETs as novel anticacer therapeutic targets, announces that its project entered the final of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
A presentation named “Anticancer Gene Therapy Platform Addressing A Novel Target to Treat Patients” is showcasing CLS Therapeutics’ data for the use of AAV-DNase (CLS-014) drug candidate to treat the most hard-to-treat, therapy-resistant tumors. Today, CLS Therapeutics revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies. The Company uses smart chimeric AAV technology for the delivery of the DNase I transgene to the liver, after which, hepatocytes start to produce a recombinant human DNase enzyme that destroys this cell-free DNA within tumor tissue.
The data will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics.
NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed) encoding DNase I of the treatment of pancreatic cancer animal model.
CLS Therapeutics Inc., an oncology focused gene therapy company, today announced that their project was selected as one of the 15 finalists to compete for the Boehringer Ingelheim Innovation Prize during the evening of August 15 at NYU Langone Health.
NEW YORK, NY / July, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).